UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 252

Sortiert nach

Next Generation Sequencing (NGS) and patient pathways: What is the impact on clinical decision?

Annals of oncology, 2018-09, Vol.29 (6), p.vi14-vi15

2018

Volltextzugriff (PDF)

Laparoscopic hysterectomy after concurrent radiochemotherapy in locally advanced cervical cancer compared to laparotomy: A multi institutional prospective pilot study of cost, surgical outcome and quality of life

European journal of surgical oncology, 2016-03, Vol.42 (3), p.391-399

2016

Volltextzugriff (PDF)

EE389 Collective vs Health Insurance Perspective in a French Efficiency Model: A Diversity of Cost Measurement Sources

Value in health, 2023-12, Vol.26 (12), p.S125

2023

Volltextzugriff (PDF)

EE233 Alternatives to Bayesian Network Meta-Analysis in Case of Proportional Hazards Invalidity: Review of HAS Cost-Utility Studies Opinions in France

Value in health, 2023-12, Vol.26 (12), p.S96

2023

Volltextzugriff (PDF)

EE151 Trade-Off between Comparators Comprehensiveness and Methodological Robustness in Cost-Utility Studies Reviewed By Has in France

Value in health, 2023-12, Vol.26 (12), p.S79

2023

Volltextzugriff (PDF)

Developing generic templates to shape the future for conducting integrated research platform trials

Trials, 2024-03, Vol.25 (1), p.204-204, Article 204

2024

Volltextzugriff (PDF)

Budget impact model for magnetic tracers in the detection of sentinel lymph nodes for operable breast cancer

European journal of cancer (1990), 2022-11, Vol.175, p.S23

2022

Volltextzugriff (PDF)

PRO34 COST-EFFECTIVENESS OF EMICIZUMAB VERSUS BY-PASSING AGENTS IN PATIENTS WITH HAEMOPHILIA A AND FVIII INHIBITORS IN FRANCE

Value in health, 2019-11, Vol.22, p.S846-S846

2019

Volltextzugriff (PDF)

PCN41 Hospital Health Care Costs for the Management of HER2-Positive Breast Cancer with Brain Metastases

Value in health, 2011, Vol.14 (7), p.A441-A441

2011

Volltextzugriff (PDF)

Etude coût-utilité d'une stratégie vaccinale dans la prévention contre les infections à méningocoques de sérogroupe C

Revue d'épidémiologie et de santé publique, 2022-05, Vol.70, p.S78-S78

2022

Volltextzugriff (PDF)

A personalized adjuvant treatment for women over 70 presenting with a luminal breast cancer? ASTER 70s or an ongoing phase III trial with parallel cohort by the UNICANCER GERICO and UCBG groups for an ongoing question

Journal of geriatric oncology, 2012-10, Vol.3, p.S34-S35

2012

Volltextzugriff (PDF)

Apport du PMSI dans l’évaluation du cancer de l’ovaire avancé

Revue d'épidémiologie et de santé publique, 2018-05, Vol.66, p.S163-S163

2018

Volltextzugriff (PDF)

Cost-Effectiveness of A Direct Aspiration First Pass Technique (ADAPT) For Thrombectomy Revascularization of Large Vessel Occlusion In Acute Ischemic Stroke (French Health Ministry Prme 16-0020)

Value in health, 2017-10, Vol.20 (9), p.A586

2017

Volltextzugriff (PDF)

PMD77 - Cost-Effectiveness of A Direct Aspiration First Pass Technique (ADAPT) For Thrombectomy Revascularization of Large Vessel Occlusion In Acute Ischemic Stroke (French Health Ministry Prme 16-0020)

Value in health, 2017-10, Vol.20 (9), p.A586-A586

2017

Volltextzugriff (PDF)

Standard or specific unit costs: Which criteria for choosing an economic evaluation of health strategies in multicentric studies?

Revue d'épidémiologie et de santé publique, 2018-03, Vol.66 Suppl 2, p.S93-S99

2018

Volltextzugriff (PDF)

PF331 COST‐EFFECTIVENESS OF EMICIZUMAB VERSUS BY‐PASSING AGENTS IN PATIENTS WITH HAEMOPHILIA A AND FVIII INHIBITORS IN FRANCE

HemaSphere, 2019-06, Vol.3 (S1), p.118-n/a

2019

Volltextzugriff (PDF)

Abstract OT2-04-01: Optisoins01: Optimizing the patient-breast cancer care pathway; An observational multicentric prospective study

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.OT2-04-01-OT2-04-01

2016

Volltextzugriff (PDF)

PMD48 - Cost Analysis of Human Genome Sequencing in Cancer Diagnosis in France: Next Generation Sequencing

Value in health, 2016-11, Vol.19 (7), p.A693-A693

2016

Volltextzugriff (PDF)

Cost Analysis of Human Genome Sequencing in Cancer Diagnosis in France: Next Generation Sequencing

Value in health, 2016-11, Vol.19 (7), p.A693-A693

2016

Volltextzugriff (PDF)

Coût du séquençage NGS à visée diagnostique en génétique somatique et constitutionnelle : estimations issues de 15 laboratoires français de génétique moléculaire des cancers

Revue d'épidémiologie et de santé publique, 2017-05, Vol.65, p.S83-S84

2017

Volltextzugriff (PDF)

Abstract OT3-4-05: Use of early CIRculating tumor CElls count changes to guide the use of chemotherapy in advanced metastatic breast cancer patients: the CirCe01 randomized trial

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.OT3-4-05-OT3-4-05

2012

Volltextzugriff (PDF)

Abstract OT3-4-06: Circulating tumor cells to guide the choice between chemotherapy and hormone therapy as first line treatment for hormone receptors positive metastatic breast cancer patients: the STIC CTC METABREAST trial

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.OT3-4-06-OT3-4-06

2012

Volltextzugriff (PDF)

Cost Of Genome Analysis: The Sanger Sequencing Method

Value in health, 2015-11, Vol.18 (7), p.A353-A353

2015

Volltextzugriff (PDF)

PMD53 - Cost Of Genome Analysis: The Sanger Sequencing Method

Value in health, 2015-11, Vol.18 (7), p.A353-A353

2015

Volltextzugriff (PDF)

1 – 25 von 252

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(232)
Mit Volltextzugriff
(234)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Next Generation Sequencing (NGS) and patient pathways: What is the impact on clinical decision?

Laparoscopic hysterectomy after concurrent radiochemotherapy in locally advanced cervical cancer compared to laparotomy: A multi institutional prospective pilot study of cost, surgical outcome and quality of life

Cost comparison of axillary sentinel lymph node detection and axillary lymphadenectomy in early breast cancer. A national study based on a prospective multi-institutional series of 985 patients ‘on behalf of the Group of Surgeons from the French Unicancer Federation’

EE389 Collective vs Health Insurance Perspective in a French Efficiency Model: A Diversity of Cost Measurement Sources

EE233 Alternatives to Bayesian Network Meta-Analysis in Case of Proportional Hazards Invalidity: Review of HAS Cost-Utility Studies Opinions in France

EE151 Trade-Off between Comparators Comprehensiveness and Methodological Robustness in Cost-Utility Studies Reviewed By Has in France

Developing generic templates to shape the future for conducting integrated research platform trials

Budget impact model for magnetic tracers in the detection of sentinel lymph nodes for operable breast cancer

PRO34 COST-EFFECTIVENESS OF EMICIZUMAB VERSUS BY-PASSING AGENTS IN PATIENTS WITH HAEMOPHILIA A AND FVIII INHIBITORS IN FRANCE

PCN41 Hospital Health Care Costs for the Management of HER2-Positive Breast Cancer with Brain Metastases

Etude coût-utilité d'une stratégie vaccinale dans la prévention contre les infections à méningocoques de sérogroupe C

A personalized adjuvant treatment for women over 70 presenting with a luminal breast cancer? ASTER 70s or an ongoing phase III trial with parallel cohort by the UNICANCER GERICO and UCBG groups for an ongoing question

Apport du PMSI dans l’évaluation du cancer de l’ovaire avancé

Cost-Effectiveness of A Direct Aspiration First Pass Technique (ADAPT) For Thrombectomy Revascularization of Large Vessel Occlusion In Acute Ischemic Stroke (French Health Ministry Prme 16-0020)

PMD77 - Cost-Effectiveness of A Direct Aspiration First Pass Technique (ADAPT) For Thrombectomy Revascularization of Large Vessel Occlusion In Acute Ischemic Stroke (French Health Ministry Prme 16-0020)

Standard or specific unit costs: Which criteria for choosing an economic evaluation of health strategies in multicentric studies?

PF331 COST‐EFFECTIVENESS OF EMICIZUMAB VERSUS BY‐PASSING AGENTS IN PATIENTS WITH HAEMOPHILIA A AND FVIII INHIBITORS IN FRANCE

Abstract OT2-04-01: Optisoins01: Optimizing the patient-breast cancer care pathway; An observational multicentric prospective study

PMD48 - Cost Analysis of Human Genome Sequencing in Cancer Diagnosis in France: Next Generation Sequencing

Cost Analysis of Human Genome Sequencing in Cancer Diagnosis in France: Next Generation Sequencing

Coût du séquençage NGS à visée diagnostique en génétique somatique et constitutionnelle : estimations issues de 15 laboratoires français de génétique moléculaire des cancers

Abstract OT3-4-05: Use of early CIRculating tumor CElls count changes to guide the use of chemotherapy in advanced metastatic breast cancer patients: the CirCe01 randomized trial

Abstract OT3-4-06: Circulating tumor cells to guide the choice between chemotherapy and hormone therapy as first line treatment for hormone receptors positive metastatic breast cancer patients: the STIC CTC METABREAST trial

Cost Of Genome Analysis: The Sanger Sequencing Method

PMD53 - Cost Of Genome Analysis: The Sanger Sequencing Method

Suchergebnisse filtern